|
[1]
|
K. B. Walker, M. J. Brennan, M. M. Ho, J. Eskola, G. Thiry, J. Sadoff, R. Dobbelaer, L. Grode, M. A. Liu, U. Fruth and P. H. Lambert, “The Second Geneva Consensus: Recommendations for Novel Live TB Vaccines,” Vaccine, Vol. 28, No. 11, 2010, pp. 2259-2270.
doi:10.1016/j.vaccine.2009.12.083
|
|
[2]
|
G. A. Colditz, C. S. Berkey, F. Mosteller, T. F. Brewer, M. E. Wilson, E. Burdick and H. V. Fineberg, “The Efficacy of Bacillus Calmette-Guerin Vaccination of New- borns and Infants in the Prevention of Tuberculosis: Meta-Analyses of the Published Literature,” Pediatrics, Vol. 96, No. 1, 1995, pp. 29-35.
|
|
[3]
|
World Health Organization (WHO), “The Work of WHO in the Eastern Mediterranean Region: Annual Report of the Regional Director,” 2009.
|
|
[4]
|
G. Sethuraman, V. Ramesh, M. Ramam and V. Sharma, “Skin Tuberculosis in Children: Learning from India,” Dermatologic Clinics, Vol. 26, No. 2, 2008, pp. 285-294.
doi:10.1016/j.det.2007.11.006
|
|
[5]
|
N. Rezaei, A. Aghamohammadi and L. Notarangelo, “Pri- mary Immunodeficiency Diseases: Definition, Diagnosis, and Management,” Springer, Berlin, 2008.
|
|
[6]
|
R. S. Geha, L. D. Notarangelo, J. L. Casanova, H. Chapel, M. E. Conley, A. Fischer, L. Hammarstr?m, S. Nonoya- ma, H. D. Ochs, J. M. Puck, C. Roifman, R. Seger and J. Wedgwood, “Primary Immunodeficiency Diseases: An Up- date from the International Union of Immunological So- cieties Primary Immunodeficiency Diseases Classification Committee,” The Journal of Allergy and Clinical Immu- nology, Vol. 120, No. 4, 2007, pp. 776-794.
doi:10.1016/j.jaci.2007.08.053
|
|
[7]
|
R. Awad, “BCG Vaccine and Post-BCG Complications among Infants in Gaza Strip, 1999,” Eastern Mediterra- nean Health Journal, Vol. 7, No. 1-2, 2001, pp. 211-220.
|
|
[8]
|
WHO, “Regional Epidemiological Data on Tuberculosis,” Eastern Mediterranean Health Journal, Vol. 2, 1996, pp. 164-166.
|
|
[9]
|
N. Ritz, “Too Much of a Good Thing: Management of BCG Vaccine Overdose,” Vaccine, Vol. 27, No. 41, 2009, pp. 5562-5564. doi:10.1016/j.vaccine.2009.07.043
|
|
[10]
|
D. Murphy, “Adverse Reactions to Mycobacterium Bovis Bacille Calmette-Guérin (BCG) Vaccination against Tuberculosis in Humans, Veterinary Animals and Wildlife Species,” Tuberculosis, Vol. 88, No. 4, 2008, pp. 344-357. doi:10.1016/j.tube.2007.11.010
|
|
[11]
|
K. Farsinejad, “Lupus Vulgaris at the Site of BCG Vaccination: Report of Three Cases,” Clinical and Experimental Dermatology, Vol. 34, No. 5, 2009, pp. e167-e169.
doi:10.1111/j.1365-2230.2008.03041.x
|
|
[12]
|
A. Santos, “Severe Axillary Lymphadenitis after BCG Vac- cination: Alert for Primary Immunodeficiencies,” Journal of Microbiology, Immunology and Infection, Vol. 43, No. 6, 2010, pp. 530-537.
doi:10.1016/S1684-1182(10)60082-5
|
|
[13]
|
M. Sadeghi-Shabestari and N. Rezaei, “Disseminated Bacille Calmette-Guérin in Iranian Children with Severe Combined Immunodeficiency,” International Journal of Infectious Diseases ,Vol. 13, No. 6, 2009, pp. e420-e423.
doi:10.1016/j.ijid.2009.02.008
|
|
[14]
|
D Shingadia and H. Baumer, “Tuberculosis, Diagnosis, Prevention and Management,” Archives of Disease in Childhood Education & Practice, Vol. 92, No. 1, 2007, pp. 27-29. doi:10.1136/adc.2006.110577
|
|
[15]
|
J. P. Guthmann, D. Antoine, L. Fonteneau, D. Che and D. Lévy-Bruhl, “Assessing BCG Vaccination Coverage and Incidence of Paediatric Tuberculosis Following Two Major Changes in BCG Vaccination Policy in France,” Euro-surveillance, Vol. 16, No. 12, 2011.
|